Circadian Clocks and Eating Patterns (Cohort)
NCT04642534 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 38
Last updated 2024-12-11
Summary
For women of reproductive age, the overall postpartum weight retention (weight gain between pregnancies) plays a significant role in long-term obesity. With 20% of women retaining ≥ 5 kg at 12 months postpartum, the risk of developing conditions, such as gestational diabetes mellitus (GDM), metabolic syndrome (MS) and subsequently diabetes and cardiovascular diseases, is substantially increased. In post-GDM mothers (women who had GDM in their recent pregnancy), postpartum weight retention is also an essential predictor of future diabetes.
Recent studies have identified the impact of circadian rhythms (influencing sleep/wake cycles) and diurnal rhythm of eating (when and how often calories are consumed over a 24h period) on cardio-metabolic disorders. In women, one remarkable feature of the postpartum period is an 'externally imposed' circadian misalignment of both sleep and eating rhythms, because most babies take several weeks to months to establish their daily pattern of activity and feeding, which is particularly relevant for breastfeeding women, as the responsibility is generally on the mother.
The overarching goal of this project is to explore the interplay between the diurnal rhythm of eating, circadian and metabolic parameters in humans. The potential postpartum effects of circadian disruption will be unraveled in women who had GDM during their pregnancy and those with an uneventful pregnancy. These women are subject to a circadian misalignment due to their 'externally imposed' changes in sleep/wake cycles and eating times in the postpartum period.
With a comprehensive approach combining molecular characterization of in vivo and in vitro circadian clock parameters along with metabolic, endocrine, transcriptomic, and lipidomic studies, the investigators will assess if eating duration and/or circadian misalignment impact on circadian clock parameters of postpartum women in a prospective cohort of 6 months.
Conditions
- Postpartum Women
- Diabetes, Gestational
Sponsors & Collaborators
-
University of Lausanne Hospitals
lead OTHER
Principal Investigators
-
Jardena Puder, MD · University of Lausanne Hospitals
-
Tinh-Hai Collet, MD · University Hospital, Geneva
Eligibility
- Min Age
- 18 Years
- Max Age
- 40 Years
- Sex
- FEMALE
- Healthy Volunteers
- Yes
Timeline & Regulatory
- Start
- 2020-02-12
- Primary Completion
- 2022-06-30
- Completion
- 2022-06-30
Countries
- Switzerland
Study Locations
More Related Trials
-
Metabolic Side-effects for Second-generation Antipsychotics
NCT01280396 ·Status: COMPLETED
-
The Effect of Dulaglutide as an Adjuvant Therapy on Cognitive Function in Bipolar Disorder Patients With Obesity
NCT06331286 ·Status: UNKNOWN ·Phase: NA
-
Monitoring of Metabolic Adverse Events of Second Generation Antipsychotics in a Naive Pediatric Population
NCT04395326 ·Status: RECRUITING
-
Effects of Herbal Products on Metabolism and Hunger
NCT00198952 ·Status: COMPLETED ·Phase: NA
-
Efficacy of Lifestyle Interventions and Metformin for the Treatment of Antipsychotic-Induced Weight Gain
NCT00451399 ·Status: COMPLETED ·Phase: PHASE4
-
Antipsychotic Medicine and Metabolic Syndrome
NCT00627757 ·Status: UNKNOWN
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications - 2
NCT01052714 ·Status: COMPLETED ·Phase: NA
-
Glucose and Lipid Metabolism on Antipsychotic Medication
NCT00515723 ·Status: COMPLETED ·Phase: NA
-
The Effects of Antipsychotic Drugs on Brain Metabolism in Healthy Individuals
NCT02536846 ·Status: COMPLETED ·Phase: PHASE4
-
Beta-carotene and Oxidative Stress in Pediatric Second Generation Antipsychotic Use
NCT02363816 ·Status: WITHDRAWN
-
Identification and Clinical Relevance of an Oxytocin Deficient State (GLP1 Study)
NCT04897802 ·Status: COMPLETED ·Phase: PHASE4
-
Monitoring and Management for Metabolic Side Effects of Antipsychotics
NCT01875861 ·Status: COMPLETED ·Phase: NA
-
Improving Cardiometabolic Health of Youth on Antipsychotic Medication
NCT02877823 ·Status: COMPLETED ·Phase: NA
-
Assessing Metabolic and Sleep Consequences of Overnight Home Parenteral Nutrition
NCT04743960 ·Status: COMPLETED ·Phase: NA
-
Antipsychotics and Metabolic Syndrome
NCT00636753 ·Status: SUSPENDED
-
In Vivo Study of Interactions Between the Endocannabinoid System and the Corticotropic Axis in Man
NCT02889224 ·Status: COMPLETED ·Phase: NA
-
Desmopressin Stimulation Test Performance in ACTH-Dependent Cushing Syndrome
NCT06635629 ·Status: RECRUITING ·Phase: PHASE2
-
Glucagon-like Peptide 1 (GLP1) Receptor Agonists and Mental Health
NCT05492305 ·Status: UNKNOWN
-
Endogenous Opioid Activity and Affective State in Insulin Resistant Women
NCT02069379 ·Status: COMPLETED ·Phase: PHASE4
-
Examination of Bromocriptine on Homeostatic and Hedonic Mechanisms of Food Intake in Individuals at High Risk for T2DM
NCT05405244 ·Status: COMPLETED ·Phase: PHASE3
-
Effects of LDX on Cognitive Processes and Appetite
NCT04181957 ·Status: TERMINATED ·Phase: NA
-
Precision Subclassification of Mental Health in Diabetes: Digital Twins for Precision Mental Health to Track Subgroups
NCT07212075 ·Status: RECRUITING
-
Metabolic Effects of Subchronic Dopamine D2 Receptor Blockade by Haloperidol in Healthy Humans
NCT00625014 ·Status: COMPLETED ·Phase: NA
-
Healthy Lifestyles for Mentally Ill People Who Have Experienced Weight Gain From Their Antipsychotic Medications
NCT00344500 ·Status: COMPLETED ·Phase: NA
-
Glycemic Index/ Load and Mental Disorders
NCT02362113 ·Status: UNKNOWN